Peter B. Gilbert

powered by
COS Expertise®
Vaccine Infectious Disease Institute
Fred Hutchinson Cancer Research Center
Biostatistics
Public Health Sciences
MemberAppointed: 2007
University of Washington
School of Public Health and Community Medicine
Biostatistics
Research ProfessorAppointed: 2008
Fred Hutchinson Cancer Research Center
Statistical Center for HIV/AIDS Research and Prevention
Co-directorAppointed: 2004

Mailing Address

Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North, M2-C200
PO Box 19024
Seattle, Washington 98109-1024
United States

Contact Information

Phone: (206) 667-7299
Fax: (206) 667-4378
pgilbert@scharp.org
http://faculty.washington.edu/peterg

Qualifications

Ph.D., University of Washington, Biostatistics, 1996.
M.S., University of Washington, Biostatistics, 1994.
B.S., University of Washington, Mathematics, 1992.

Expertise and Research Interests

Clinical trials for HIV vaccines.
Statistical methods in the areas of survival analysis, genetic sequence analysis, surrogate endpoints, causal inference.

Other Expertise

For my complete CV including publications go to http://faculty.washington.edu/peterg

Keywords

COS Keywords:

AIDS, Biometry, Biostatistics, Clinical Trial, HIV, HIV Prevention, Statistics, Vaccine.

Additional Terms:

Clinical Trials, HIV Vaccine Research, Statistical Methods.

Memberships

American Statistical Association
International Biometrics Society

Honors and Awards

2005-2006, Ross L. Prentice Professorship, University of Washington, Department of Biostatistics
2000-2001, Excellent Teaching Rating, Harvard School of Public Health
1996, Senior Biostatistics Student Award, University of Washington
1995, Outstanding Student Scholarship, University of Washington, School of Public Health and Community Medicine
1994, Honorary Donovan J. Thompson Award, University of Washington, Outstanding Performance as Student in Biostatistics
1992, Phi Beta Kappa, University of Washington
1992, National Honor Society, Golden Key
1992, B.S., Magna Cum Laude, University of Washington
1988-1992, Dean's List, University of Washington

Previous Positions

2005-2006, Deputy Director of Statistical Sciences, Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP)
2004-2008, Research Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
2002-2004, Research Assistant Professor, University of Washington, School of Public Health and Community Medicine, Department of Biostatistics
2002-2007, Associate Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
2001-2002, Assistant Member, Fred Hutchinson Cancer Research Center
1997, Research Fellow, Harvard University, School of Public Health
1997-2001, Assistant Professor, Harvard University, School of Public Health, Biostatistics
1995-1996, Graduate Research Assistant, University of Washington, HIVNET

Funding Received

  • NIH-NIAID: Statistical Methods in HIV Vaccine Efficacy Trials, 2006 to 2010.
  • NIH-SBIR Fast Track Grant: Determining Correlates of Protection Against HIV Infection, 2004 to 2005.
  • NIH-NIAID: Statistical Methods in HIV Vaccine Efficacy Trials, 2003 to 2006.
  • NIH-NIAID: HIV Vaccine Trials Network Leadership Group, 2000 to 2005.

Publications

  • Gilbert PB, McKeague IW, Sun Y (Apr 2008) The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy., Biostatistics (Oxford, England), 9 (2), 263-76 Abstract
  • Gilbert PB, Hudgens MG (Mar 2008) Evaluating Candidate Principal Surrogate Endpoints., Biometrics Abstract
  • Sun Y, Hyun S, Gilbert P (Mar 2008) Testing and Estimation of Time-Varying Cause-Specific Hazard Ratios with Covariate Adjustment., Biometrics Abstract
  • Gilbert PB, Wu C, Jobes DV (Mar 2008) Genome scanning tests for comparing amino acid sequences between groups., Biometrics, 64 (1), 198-207 Abstract
  • Gilbert PB, Qin L, Self SG (Nov 2007) Evaluating a surrogate endpoint at three levels, with application to vaccine development., Statistics in medicine Abstract
  • Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (Nov 2007) A framework for assessing immunological correlates of protection in vaccine trials., The Journal of infectious diseases, 196 (9), 1304-12 Abstract
  • Hudgens MG, Maathuis MH, Gilbert PB (Jun 2007) Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variable., Biometrics, 63 (2), 372-80 Abstract
  • Forthal DN, Gilbert PB, Landucci G, Phan T (May 2007) Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate., Journal of immunology (Baltimore, Md. : 1950), 178 (10), 6596-603 Abstract
  • Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast P, Cardinali M, Self S (Jan 2007) Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop., Journal of acquired immune deficiency syndromes (1999), 44 (1), 49-60 Abstract
  • Li F, Gilbert PB, Self SG (Jan 2007) Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach., Current HIV research, 5 (1), 87-96 Abstract
  • Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG (Jan 2007) HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features., Current HIV research, 5 (1), 97-107 Abstract
  • Nickle DC, Heath L, Jensen MA, Gilbert PB, Mullins JI, Kosakovsky Pond SL (2007) HIV-specific probabilistic models of protein evolution., PLoS ONE, 2 (6), e503 Abstract
  • Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K (Dec 2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand., The Journal of infectious diseases, 194 (12), 1661-71 Abstract
  • Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG (Nov 2006) Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation., Vaccine, 24 (47-48), 6893-904 Abstract
  • Gilbert P (Oct 2006) Avoiding the resistance pitfall in infection control. Does the use of antiseptic products contribute to the spread of antibiotic resistance?, Ostomy/wound management, 52 (10A Suppl), 1S-3S Abstract
  • Mehrotra DV, Li X, Gilbert PB (Sep 2006) A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial., Biometrics, 62 (3), 893-900 Abstract
  • Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, Gilbert PB, Stevens L, Peter T, Kim S, van Widenfelt E, Moffat C, Ndase P, Arimi P, Kebaabetswe P, Mazonde P, Makhema J, McIntosh K, Novitsky V, Lee TH, Marlink R, Lagakos S, Essex M (Aug 2006) Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study., JAMA : the journal of the American Medical Association, 296 (7), 794-805 Abstract
  • Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, Stevens L, Heymann SJ, Ndung'u T, Gaseitsiwe S, Novitsky V, Makhema J, Lagakos S, Essex M (Jun 2006) Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana., AIDS (London, England), 20 (9), 1281-8 Abstract
  • Wick WD, Gilbert PB, Self SG (Jun 2006) On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials., PLoS computational biology, 2 (6), e64 Abstract
  • Shepherd BE, Gilbert PB, Jemiai Y, Rotnitzky A (Jun 2006) Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials., Biometrics, 62 (2), 332-42 Abstract
  • Novitsky VA, Gilbert PB, Shea K, McLane MF, Rybak N, Klein I, Thior I, Ndung'u T, Lee TH, Essex ME (May 2006) Interactive association of proviral load and IFN-gamma-secreting T cell responses in HIV-1C infection., Virology, 349 (1), 142-55 Abstract
  • Ndung'u T, Sepako E, McLane MF, Chand F, Bedi K, Gaseitsiwe S, Doualla-Bell F, Peter T, Thior I, Moyo SM, Gilbert PB, Novitsky VA, Essex M (Apr 2006) HIV-1 subtype C in vitro growth and coreceptor utilization., Virology, 347 (2), 247-60 Abstract
  • Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND (Apr 2006) Statistical evaluation of HIV vaccines in early clinical trials., Contemporary clinical trials, 27 (2), 147-60 Abstract
  • Cai T, Gilbert PB, Self SG (2006) Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial., Journal of biopharmaceutical statistics, 16 (4), 517-38 Abstract
  • Gilbert PB, Novitsky V, Essex M (Dec 2005) Covariability of selected amino acid positions for HIV type 1 subtypes C and B., AIDS research and human retroviruses, 21 (12), 1016-30 Abstract
  • Meier AS, Gilbert PB (Oct 2005) Accuracy and precision of estimating intervention efficacy when the timing of observed events differ by treatment arm., Contemporary clinical trials, 26 (5), 598-610 Abstract
  • Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M (Sep 2005) HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine., The Journal of infectious diseases, 192 (6), 974-83 Abstract
  • Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC (Aug 2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines., Journal of virology, 79 (16), 10103-7 Abstract
  • Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC (Aug 2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies., Journal of virology, 79 (16), 10108-25 Abstract
  • Gilbert PB, Sun Y (Jul 2005) Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation., Biostatistics (Oxford, England), 6 (3), 374-94 Abstract
  • Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW (Mar 2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial., The Journal of infectious diseases, 191 (5), 666-77 Abstract
  • Gilbert PB, Rossini AJ, Shankarappa R (Mar 2005) Two-sample tests for comparing intra-individual genetic sequence diversity between populations., Biometrics, 61 (1), 106-17 Abstract
  • Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL (Sep 2004) Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160., The Journal of infectious diseases, 190 (5), 903-7 Abstract
  • Hudgens MG, Gilbert PB, Self SG (Apr 2004) Endpoints in vaccine trials., Statistical methods in medical research, 13 (2), 89-114 Abstract
  • Gilbert PB, McKeague IW, Sun Y (Mar 2004) Tests for comparing mark-specific hazards and cumulative incidence functions., Lifetime data analysis, 10 (1), 5-28 Abstract
  • Gilbert P, Esparza J (2004) Simultaneous inferences of HIV vaccine effects on viral load, CD4 cell counts, and antiretroviral therapy initiation in Phase 3 trials, Deterministic and Stochastic Models of HIV with Intervention, Tan and H. Wu (bookchapter)
  • Gilbert PB, Bosch RJ, Hudgens MG (Sep 2003) Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials, Biometrics, 59 (3), 531-41
  • Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L (Jul 2003) What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials., The Journal of infectious diseases, 188 (2), 179-93 Abstract
  • Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE (Jun 2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials., Vaccine, 21 (21-22), 2933-47 Abstract
  • Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ (Feb 2003) Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal., Statistics in medicine, 22 (4), 573-93 Abstract
  • Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, Rybak N, Thior I, Ndung'u T, Marlink R, Lee TH, Essex M (Jan 2003) Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection., Journal of virology, 77 (2), 882-90 Abstract
  • Gilbert PB, Wei LJ, Kosorok MR, Clemens JD (Dec 2002) Simultaneous inferences on the contrast of two hazard functions with censored observations., Biometrics, 58 (4), 773-80 Abstract
  • Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T, Thior I, Ndung'u T, Marlink R, Lee TH, Essex M (Oct 2002) Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C., Journal of virology, 76 (20), 10155-68 Abstract
  • Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, Ndung'u T, Klein I, Chang SY, Peter T, Thior I, Foley BT, Gaolekwe S, Rybak N, Gaseitsiwe S, Vannberg F, Marlink R, Lee TH, Essex M (Jun 2002) Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?, Journal of virology, 76 (11), 5435-51 Abstract
  • Gilbert, P, Sun Y (2002) HIV-1 vaccine testing, trial design and ethics., AIDS in Africa, Second Edition, New York, Kluwer Academic (bookchapter)
  • Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P, Klein I, Gaolekwe S, Chang SY, Peter T, Thior I, Ndung'u T, Vannberg F, Foley BT, Marlink R, Lee TH, Essex M (Oct 2001) Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design., Journal of virology, 75 (19), 9210-28 Abstract
  • McKeague IW, Gilbert PB, Kanki PJ (Sep 2001) Omnibus tests for comparison of competing risks with adjustment for covariate effects., Biometrics, 57 (3), 818-28 Abstract
  • Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK (Jul 2001) Prevalence and predictive value of intermittent viremia with combination hiv therapy., JAMA : the journal of the American Medical Association, 286 (2), 171-9 Abstract
  • Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK, Richman DD (Jul 2001) Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression., AIDS (London, England), 15 (11), 1379-88 Abstract
  • DeGruttola V, Hughes M, Gilbert P, Phillips A (1998) Trial design in the era of highly effective antiviral drug combinations for HIV infection., AIDS (London, England), 12 Suppl A, S149-56 Abstract

Profile Details

Last Updated: 2/24/2009

COS Expertise ID #1214125
Reference this profile directly: http://myprofile.cos.com/peterg